[go: up one dir, main page]

CL2018002337A1 - Pharmaceutical composition to prevent and treat sleep disorders - Google Patents

Pharmaceutical composition to prevent and treat sleep disorders

Info

Publication number
CL2018002337A1
CL2018002337A1 CL2018002337A CL2018002337A CL2018002337A1 CL 2018002337 A1 CL2018002337 A1 CL 2018002337A1 CL 2018002337 A CL2018002337 A CL 2018002337A CL 2018002337 A CL2018002337 A CL 2018002337A CL 2018002337 A1 CL2018002337 A1 CL 2018002337A1
Authority
CL
Chile
Prior art keywords
sleep disorders
prevent
pharmaceutical composition
treat sleep
composition
Prior art date
Application number
CL2018002337A
Other languages
Spanish (es)
Inventor
Vladimir Viktorovich Nesteruk
Kirill Konstantinovich Syrov
Original Assignee
Valenta Intellekt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valenta Intellekt Ltd filed Critical Valenta Intellekt Ltd
Publication of CL2018002337A1 publication Critical patent/CL2018002337A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN SE REFIERE AL CAMPO DE LA MEDICINA Y DE LA INDUSTRIA QUÍMICO-FARMACÉUTICA Y PERTENECE A AGENTES PARA SU USO EN EL CASO DE TRASTORNOS DEL SUEÑO. UNA COMPOSICIÓN FARMACÉUTICA PARA INICIAR Y MANTENER EL PROCESO DEL SUEÑO Y PARA PREVENIR, EN ANIMALES Y EN SERES HUMANOS, AFECCIONES ASOCIADAS A DIVERSOS TIPOS DE TRASTORNOS DEL SUEÑO, CARACTERIZÁNDOSE DICHA COMPOSICIÓN POR QUE INCLUYE CANTIDADES EFICACES DE SUCCINATO DE DOXILAMINA Y MELATONINA DE LIBERACIÓN LENTA. EL RESULTADO TÉCNICO CONSISTE EN EFECTOS TERAPÉUTICOS SINÉRGICOS, SUCESIÓN BIOLÓGICA Y EFECTOS SECUNDARIOS REDUCIDOS.THE INVENTION REFERS TO THE FIELD OF MEDICINE AND THE CHEMICAL-PHARMACEUTICAL INDUSTRY AND BELONGS TO AGENTS FOR USE IN THE CASE OF SLEEP DISORDERS. A PHARMACEUTICAL COMPOSITION TO INITIATE AND MAINTAIN THE DREAM PROCESS AND TO PREVENT, IN ANIMALS AND IN HUMAN BEINGS, AFFECTIONS ASSOCIATED WITH DIFFERENT TYPES OF SLEEP DISORDERS, CHARACTERIZING SUCH COMPOSITION THAT INCLUDES LATININATION OF STIMATINATION. THE TECHNICAL RESULT CONSISTS OF SYNERGIC THERAPEUTIC EFFECTS, BIOLOGICAL SUCCESSION AND REDUCED SECONDARY EFFECTS.

CL2018002337A 2016-02-18 2018-08-16 Pharmaceutical composition to prevent and treat sleep disorders CL2018002337A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2016105535A RU2620855C1 (en) 2016-02-18 2016-02-18 Pharmaceutical composition for sleep disorders prevention and treatment

Publications (1)

Publication Number Publication Date
CL2018002337A1 true CL2018002337A1 (en) 2018-11-30

Family

ID=59032329

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002337A CL2018002337A1 (en) 2016-02-18 2018-08-16 Pharmaceutical composition to prevent and treat sleep disorders

Country Status (9)

Country Link
KR (1) KR20180101539A (en)
CN (1) CN108697645A (en)
BR (1) BR112018016725A2 (en)
CL (1) CL2018002337A1 (en)
EA (1) EA201891647A1 (en)
HK (1) HK1255631A1 (en)
MX (1) MX2018009921A (en)
RU (1) RU2620855C1 (en)
WO (1) WO2017142442A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
EP2717698A4 (en) * 2011-06-09 2015-01-07 Requis Pharmaceuticals Inc ANTIHISTAMINES COMBINED WITH FOOD SUPPLEMENTS TO IMPROVE HEALTH
FR3000896B1 (en) * 2013-01-14 2016-08-26 Philippe Perovitch GALENIC FORM FOR ADMINISTRATION OF ACTIVE INGREDIENT (S) FOR ACCELERATED INDUCTION OF SLEEP AND / OR TREATMENT OF SLEEP DISORDERS
WO2014138162A1 (en) * 2013-03-05 2014-09-12 Requis Pharmaceuticals Inc. Preparations for the treatment of sleep-related respiratory disorders

Also Published As

Publication number Publication date
EA201891647A1 (en) 2018-12-28
RU2620855C1 (en) 2017-05-30
WO2017142442A1 (en) 2017-08-24
HK1255631A1 (en) 2019-08-23
BR112018016725A2 (en) 2019-04-30
CN108697645A (en) 2018-10-23
MX2018009921A (en) 2018-11-09
KR20180101539A (en) 2018-09-12

Similar Documents

Publication Publication Date Title
CL2016002517A1 (en) Use of r-2-4-2-ethoxy-3-4-trifluoromethylphenoxypropyl-thio-2-methylphenoxy acetic acid or a salt thereof in the manufacture of a medicament to treat a condition that is a non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
MX2020013104A (en) Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease.
UY35907A (en) NEW INDAZOLCARBOXAMIDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
CO2017012381A2 (en) Mono or disubstituted indole derivatives as inhibitors of dengue viral replication
MX2016010179A (en) COMPOSITIONS OF DONEPEZILO AND METHODS TO TREAT ALZHEIMER'S DISEASE.
MX2017006113A (en) Novel polymeric hgh prodrugs.
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
MX2016015437A (en) COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101.
ECSP16086247A (en) (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2017013636A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from different particles.
MX2017001461A (en) Combination therapy.
MX2016011025A (en) GRAPIPRANT COMPOSITIONS AND METHODS TO USE THE SAME.
ECSP16086232A (en) (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
CL2016001843A1 (en) Use of a composition comprising a) a compound of defined formula (ia) or a salt thereof and b) a pharmaceutically acceptable carrier or excipient to prepare a medicament useful for treating an allergic condition in a mammal.
MX2017013633A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO PHARMACES FROM PARTICLES.
MX2017013643A (en) Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix.
MX2017013634A (en) FIXED DOSE COMBINATION RESISTANT TO HANDLING THAT PROVIDES A QUICK RELEASE OF TWO DRUGS FROM PARTICLES AND A POWDER.
CL2018002337A1 (en) Pharmaceutical composition to prevent and treat sleep disorders
AR110374A1 (en) DOSED FORMS OF MODIFIED GASTRORETENTIVE RELEASE FOR OPROZOMIB AND PROCESS FOR MANUFACTURING
MX2019009909A (en) Pharmaceutical compositions for combination therapy.
UY37413A (en) OPROZOMIB IMMEDIATE RELEASE FORMULATIONS
AR106415A1 (en) PHARMACEUTICAL COMPOSITION FOR PAIN TREATMENT
AR103636A1 (en) METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.